Skip to main content
SpringerLink
Log in

Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Purpose

Down-regulation of thyroid hormone receptor beta (THRβ) gene has been described in several human malignancies, including thyroid cancer. In this study, we analyzed THRβ mRNA expression in surgical specimens from a series of human papillary thyroid carcinomas (PTCs), characterized by their genotypic and clinical–biological features.

Methods

Thirty-six PTCs were divided into two groups according to the 2009 American Thyroid Association risk classification (17 low, 19 intermediate), and each group was divided into subgroups based on the presence or absence of the BRAFV600E mutation (21 BRAF mutated, 15 BRAF wild type). Gene expression was analyzed using fluidic cards containing probes and primers specific for the THRβ gene, as well as for genes of thyroperoxidase (TPO), sodium/iodide symporter (NIS), thyroglobulin (Tg) and thyroid stimulating hormone receptor (TSH-R) and for some miRNAs involved in thyroid neoplasia and targeting THRβ. The mRNA levels of each tumor tissue were compared with their correspondent normal counterpart.

Results

THRβ transcript was down-regulated in all PTCs examined. No significant differences were found between intermediate- vs low-risk PTCs patients, and BRAF-mutated vs BRAF wild-type groups. THRβ expression was directly correlated with NIS, TPO, Tg and TSH-R, and inversely correlated to miR-21, -146a, -181a and -221 expression.

Conclusions

Our results demonstrate that down-regulation of THRβ is a common feature of PTCs. While it is not associated with a more aggressive phenotype of PTC, it correlates with the reduction of all the markers of differentiation and is associated with overexpression of some miRNAs supposed to play a role in thyroid tumorigenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Cheng SY (2000) Multiple mechanisms for regulation of the transcriptional activity of thyroid hormone receptors. Rev Endocr Metab Disord 1:9–18

    Article  CAS  PubMed  Google Scholar 

  2. Kim WG, Cheng SY (2013) Thyroid hormone receptors and cancer. Biochim Biophys Acta 1830:3928–3936

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Li Z, Meng ZH, Chandrasekaran R, Kuo WL, Collins CC, Gray JW, Diarkee SH (2002) Biallelic inactivation of the thyroid hormone receptor β1 gene in early stage breast cancer. Cancer Res 62:1939–1943

    CAS  PubMed  Google Scholar 

  4. Ling Y, Xu X, Hao J, Ling X, Du X, Liu X, Zhao X (2010) Aberrant methylation of the THRB gene in tissue and plasma of breast cancer patients. Cancer Genet Cytogenet 196:140–145

    Article  CAS  PubMed  Google Scholar 

  5. Lin KH, Shieh HY, Chen SL, Hsu HC (1999) Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol Carcinog 26:53–61

    Article  CAS  PubMed  Google Scholar 

  6. Futreal PA, Cochran C, Marks JR, Iglehart JD, Zimmerman W, Barret JC, Wiseman RW (1994) Mutation analysis of the THRA1 gene in breast cancer: deletion/fusion of the gene to a novel sequence on 17q in the BT474 cell line. Cancer Res 54:1791–1794

    CAS  PubMed  Google Scholar 

  7. Dobrovic A, Houle B, Belouchi A, Bradley WE (1988) erbA-related genes coding for DNA-binding hormone receptors localized to chromosome 3p21-3p25 and deleted in small cell lung carcinoma. Cancer Res 48:682–685

    CAS  PubMed  Google Scholar 

  8. Sisley K, Kurtis D, Rennie IG, Rees RC (1993) Loss of heterozygosity of the thyroid hormone receptor β in posterior uveal melanoma. Melanoma Res 3:457–461

    Article  CAS  PubMed  Google Scholar 

  9. Martinez-Iglesias O, Garcia-Silva S, Tenbaum SP, Regadera J, Larcher F, Paramio JM, Vennström B, Aranda A (2009) Thyroid hormone receptor β1 acts as a potent suppressor of tumor invasiveness and metastasis. Cancer Res 69(2):501–509

    Article  CAS  PubMed  Google Scholar 

  10. Kim WG, Zhu X, Kim DW, Zhang L, Kebebew E, Cheng SY (2013) Reactivation of the silenced thyroid hormone receptor β gene expression delays thyroid tumor progression. Endocrinology 154:25–35

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Zhu XG, Zhao L, Willingham MC, Cheng SY (2010) Thyroid hormone receptors are tumor suppressors in a mouse model of metastatic follicular thyroid carcinoma. Oncogene 29:1909–1919

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Fernando AA, Dowing JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expression profiles classify human cancers. Nature 435:834–838

    Article  CAS  PubMed  Google Scholar 

  13. Adams BD, Kasinski AL, Slack FJ (2014) Aberrant regulation and function of microRNAs in cancer. Curr Biol 24(16):R762–R776

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Hayes J, Peruzzi PP, Lawler S (2014) MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 20(8):460–469

    Article  CAS  PubMed  Google Scholar 

  15. Pallante P, Battista S, Pierantoni GM, Fusco A (2014) Deregulation of microRNA expression in thyroid neoplasias. Nat Rev Endocrinol 10:88–101

    Article  CAS  PubMed  Google Scholar 

  16. Dettmer MS, Perren A, Moch H, Komminoth P, Nikiforov YE, Nikiforova MN (2014) MicroRNA profile of poorly differentiated thyroid carcinomas–new diagnostic and prognostic insights. J Mol Endocrinol 52:181–189

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Jazdzewski K, Boguslawska J, Jendrzejewski J, Liyanarachchi S, Pachucki J, Wardyn KA, Nauman A, De la Chapelle A (2011) Thyroid hormone receptor β (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC). J Clin Endocrinol Metab 96:E546–E553

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474

    Article  PubMed  Google Scholar 

  19. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM (2009) Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214

    Article  PubMed  Google Scholar 

  20. Sponziello M, Bruno R, Durante C, D’Agostino M, Corradino R, Giannasio P, Ciociola E, Ferretti E, Maranghi M, Verrienti A, De Toma G, Filetti S, Russo D (2011) Growth factor receptors gene expression and Akt phosphorylation in benign human thyroid nodules are unaffected by chronic thyrotropin suppression. Horm Metab Res 43:22–25

    Article  CAS  PubMed  Google Scholar 

  21. D’Agostino M, Sponziello M, Puppin C, Celano M, Maggisano V, Baldan F, Biffoni M, Bulotta S, Durante C, Filetti S, Damante G, Russo D (2014) Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics. J Mol Endocrinol 52:121–131

    Article  PubMed  Google Scholar 

  22. Sponziello M, Lavarone E, Pegolo E, Di Loreto C, Puppin C, Russo MA, Bruno R, Filetti S, Durante C, Russo D, Di Cristofano A, Damante G (2013) Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer. Endocrinology 154:3043–3053

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Davies L, Welch HG (2014) Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 140:317–322

    Article  PubMed  Google Scholar 

  24. Arturi F, Russo D, Giuffrida D, Schlumberger M, Filetti S (2000) Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas. Eur J Endocrinol 143:623–627

    Article  CAS  PubMed  Google Scholar 

  25. Arturi F, Russo D, Bidart JM, Scarpelli D, Schlumberger M, Filetti S (2001) Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors. Eur J Endocrinol 145:129–135

    Article  CAS  PubMed  Google Scholar 

  26. Kogai T, Brent GA (2012) The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol Ther 135:355–370

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Schlumberger M, Lacroix L, Russo D, Filetti S, Bidart JM (2007) Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Clin Pract Endocrinol Metab 3:260–269

    Article  CAS  PubMed  Google Scholar 

  28. Fagin JA, Mitsiades N (2008) Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 22:955–969

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Russo D, Damante G, Puxeddu E, Durante C, Filetti S (2011) Epigenetics of thyroid cancer and novel therapeutic targets. J Mol Endocrinol 46:R73–R81

    Article  CAS  PubMed  Google Scholar 

  30. Xing M (2013) Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 13:184–199

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Galrão AL, Sodré AK, Camargo RY, Friguglietti CU, Kulcsar MA, Lima EU, Medeiros-Neto G, Rubio IG (2013) Methylation levels of sodium-iodide symporter (NIS) promoter in benign and malignant thyroid tumors with reduced NIS expression. Endocrine 43:225–229

    Article  PubMed  Google Scholar 

  32. Puzianowska-Kuznicka M, Krystyniak A, Madej A, Cheng SY, Nauman J (2002) Functionally impaired TR mutants are present in thyroid papillary cancer. J Clin Endocrinol Metab 87(3):1120–1128

    Article  CAS  PubMed  Google Scholar 

  33. Ciampi R, Nikiforov YE (2005) Alterations of the BRAF gene in thyroid tumors. Endocr Pathol 16:163–172

    Article  CAS  PubMed  Google Scholar 

  34. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S, Russo D (2007) BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 92(7):2840–2843

    Article  CAS  PubMed  Google Scholar 

  35. Puxeddu E, Durante C, Avenia N, Filetti S, Russo D (2008) Clinical implication of BRAF mutation in thyroid carcinoma. Trends Endocrinol Metab 19:138–145

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the Fondazione Umberto Di Mario and by Banca d’Italia.

Conflict of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Ethical approval

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

The authors declare that informed consent was obtained from all individual participants included in the study.

Author information

Author notes

    Authors and Affiliations

    1. Department of Internal Medicine and Medical Specialties, University of Rome “Sapienza”, Viale del Policlinico155, 00161, Rome, Italy

      F. Rosignolo, M. Sponziello, A. Verrienti, M. Dima, V. Pecce & C. Durante

    2. Department of Health Sciences, University of Catanzaro ‘Magna Graecia’, 88100, Catanzaro, Italy

      V. Maggisano, M. Celano & M. D’Agostino

    3. Department of Radiological, Oncological and Pathological Sciences, University of Rome “Sapienza”, 00161, Rome, Italy

      C. R. T. Di Gioia

    4. Department of Surgical Sciences, University of Rome “Sapienza”, 00161, Rome, Italy

      L. Giacomelli

    Authors
    1. F. Rosignolo
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. V. Maggisano
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. M. Sponziello
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. M. Celano
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. C. R. T. Di Gioia
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. M. D’Agostino
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. L. Giacomelli
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. A. Verrienti
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. M. Dima
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. V. Pecce
      View author publications

      You can also search for this author in PubMed Google Scholar

    11. C. Durante
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to C. Durante.

    Additional information

    F. Rosignolo and V. Maggisano equally contributed to this work.

    Electronic supplementary material

    Below is the link to the electronic supplementary material.

    40618_2015_309_MOESM1_ESM.ppt

    Fig. S1 Correlation between miRNAs and thyroid-specific genes in human PTCs mRNA levels of TPO are significantly and inversely correlated to expression levels of miR-21 (a). mRNA levels of TG are significantly and inversely correlated to expression levels of miR-21 (b) and miR-146a (c). Correlations between miRNAs and thyroid-specific genes were analyzed by the Spearman rho rank correlation coefficient. Supplementary material 1 (PPT 248 kb)

    Supplementary material 2 (DOC 104 kb)

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Rosignolo, F., Maggisano, V., Sponziello, M. et al. Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression. J Endocrinol Invest 38, 1283–1289 (2015). https://doi.org/10.1007/s40618-015-0309-4

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40618-015-0309-4

    Keywords

    Search

    Navigation